Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.

about

Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer.

P2860

Q37407245-42BBA8B9-9D0B-49C5-BD2C-3706832F5045

P2860

Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.

Item

http://www.wikidata.org/entity/Q36662504

description

2016 nî lūn-bûn

@nan

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@ast

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@en

type

Item

label

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@ast

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@en

prefLabel

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@ast

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@en

P1476

Epidermal growth factor recept ...... carcinoma patients in Kuwait.

@en

P2093

Bushra Al-Ayadhy

http://www.w3.org/2001/XMLSchema#string

Issam M Francis

http://www.w3.org/2001/XMLSchema#string

Kusum Kapila

http://www.w3.org/2001/XMLSchema#string

Salah Al-Waheeb

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

Molecular pathology of lung cancer: key to personalized medicine.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0970-9371.175476

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fahd Al-mulla

Rabeah Al-Temaimi

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27011433

http://www.w3.org/2001/XMLSchema#string

P932

4782395

http://www.w3.org/2001/XMLSchema#string

Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.

about

P2860

P2860

Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932